Axovant Licenses Investigational Gene Therapies for GM1 Gangliosidosis, Tay-Sachs and Sandhoff Diseases from University of Massachusetts Medical School
Two novel programs for fatal pediatric diseases deepen Axovant’s neurological gene therapy pipeline AXO-AAV-GM1 expected to enter the clinic in […]